Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South-East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease-Emerging Nations' Consortium

Banerjee, Rupa and Pal, Partha and Hilmi, Ida Normiha and Ghoshal, Uday C. and Desai, Devendra C. and Rahman, Mohammed Masudur and Dutta, Usha and Mohiuddin, Syed A. and Al Mohannadi, Munnera and Philip, Mathew and Ramesh, Ganesh N. and Niriella, Madunil A. and De Silva, Arjuna P. and de Silva, Hithanadura Janaka and Pisespongsa, Pises and Limsrivilai, Julajak and Aniwan, Satimai and Nawarathne, Metthananda and Fernandopulle, Nilesh and Aye, Than Than and Ni, Nwe and Al Awadhi, Sameer and Joshi, Neeraj and Ngoc, Pham Thi and Kieu, Tuan and Nguyen, Anh Duong and Abdullah, Murdani and Ali, Ezzat and Zeid, Ahmed and Sollano, Jose D. and Saberi, Bismillah and Omar, Mahmoud and Mohsin, Mostafa Noor and Aftab, Hafeza and Wai, Tin Moe and Shastri, Yogesh M. and Chaudhuri, Sujit and Ahmed, Faruque and Bhatia, Shobna J. and Travis, Simon P. L. and Dis-Emergin, Inflammatory Bowel (2022) Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South-East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease-Emerging Nations' Consortium. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 37 (6). pp. 1004-1015. ISSN 0815-9319, DOI https://doi.org/10.1111/jgh.15801.

Full text not available from this repository.

Abstract

Background and Aim Inflammatory bowel disease (IBD) is emerging in the newly industrialized countries of South Asia, South-East Asia, and the Middle East, yet epidemiological data are scarce. Methods We performed a cross-sectional study of IBD demographics, disease phenotype, and treatment across 38 centers in 15 countries of South Asia, South-East Asia, and Middle East. Intergroup comparisons included gross national income (GNI) per capita. Results Among 10 400 patients, ulcerative colitis (UC) was twice as common as Crohn's disease (CD), with a male predominance (UC 6678, CD 3495, IBD unclassified 227, and 58% male). Peak age of onset was in the third decade, with a low proportion of elderly-onset IBD (5% age > 60). Familial IBD was rare (5%). The extent of UC was predominantly distal (proctitis/left sided 67%), with most being treated with mesalamine (94%), steroids (54%), or immunomodulators (31%). Ileocolic CD (43%) was the commonest, with low rates of perianal disease (8%) and only 6% smokers. Diagnostic delay for CD was common (median 12 months; interquartile range 5-30). Treatment of CD included mesalamine, steroids, and immunomodulators (61%, 51%, and 56%, respectively), but a fifth received empirical antitubercular therapy. Treatment with biologics was uncommon (4% UC and 13% CD), which increased in countries with higher GNI per capita. Surgery rates were 0.1 (UC) and 2 (CD) per 100 patients per year. Conclusions The IBD-ENC cohort provides insight into IBD in South-East Asia and the Middle East, but is not yet population based. UC is twice as common as CD, familial disease is uncommon, and rates of surgery are low. Biologic use correlates with per capita GNI.

Item Type: Article
Funders: None
Uncontrolled Keywords: IBD-ENC; inflammatory bowel disease; Middle East; South Asia; South-East Asia
Subjects: R Medicine
Divisions: Faculty of Medicine
Depositing User: Ms. Juhaida Abd Rahim
Date Deposited: 15 Oct 2023 02:35
Last Modified: 15 Oct 2023 02:35
URI: http://eprints.um.edu.my/id/eprint/42328

Actions (login required)

View Item View Item